Comprehensive CDMO solutions spanning synthetic route design, high-containment payload-linker synthesis, and bioconjugation optimization. Backed by a proven track record of successfully delivered client campaigns, we bridge complex targeted chemistry with regulatory scale-up.
Integrated ADC Solutions: Linker-Payload Synthesis & Bioconjugation
Precision Targeting Chemistry Backed by Proven Project Execution
Antibody–Drug Conjugates represent one of the most sophisticated frontiers in targeted oncology. At Anax Laboratories, we deliver end-to-end development and manufacturing solutions covering the entire small-molecule and conjugation spectrum of ADCs. From designing high-purity, stable linker architectures to synthesizing highly potent cytotoxic payloads and executing site-specific bioconjugation, our team ensures reproducible drug-to-antibody ratios (DAR) and batch-to-batch structural integrity.
Track Record & Proven Execution
With multiple successfully completed client projects, Anax has established a reliable track record in navigating the synthetic and analytical complexities of ADC development:
- Delivered Custom Payload-Linker Campaigns: Successfully synthesized and scaled multi-step, patent-free linkers and potent payloads with high chiral and diastereomeric purity.
- Complex Conjugation Milestones: Executed scalable conjugation protocols for diverse target proteins, achieving tight, reproducible DAR distributions and low aggregate profiles.
- Rapid Preclinical-to-Pilot Transition: Supported biotech and pharma partners with rapid multi-gram delivery of novel constructs for early screening, followed by scalable process development.
Core Capabilities Across the ADC Value Chain
1. Potent Payload Synthesis (SafeBridge Cat 3/4 Containment)
- Synthetic route scouting and scalable manufacturing of ultra-potent cytotoxic warheads.
- Expertise across major payload classes: Auristatins (e.g., MMAE, MMAF), Maytansinoids (e.g., DM1, DM4), Topoisomerase I inhibitors (e.g., Camptothecin/SN-38 derivatives), and novel DNA-damaging payloads.
- Complete synthesis, purification, and handling under low-OEL negative-pressure barrier isolators.
2. Engineered Linker Design & Scaled Manufacturing
- Cleavable Linkers: Advanced multi-step synthesis of enzyme-sensitive (Val-Cit, Val-Ala), acid-sensitive (hydrazone), and glutathione-sensitive (disulfide) linkers engineered for selective intracellular release.
- Non-Cleavable Linkers: Stable thioether-based spacers (e.g., SMCC) designed for prolonged systemic circulation and minimal off-target toxicity.
- Solubility & Spacer Engineering: Incorporation of discrete monodisperse PEG (polyethylene glycol) chains and self-immolative motifs to enhance conjugate solubility and prevent in vivo aggregation.
3. Bioconjugation Process Development & DAR Control
- Systematic optimization of conjugation chemistry:
- Native amino acid conjugation (surface Lysine residues, interchain Cysteine thiols).
- Site-specific bioconjugation technologies to ensure homogenous, predictable DAR profiles.
- Design of Experiments (DoE) workflows to optimize stoichiometry, buffer exchange, pH, and reaction kinetics while preserving monoclonal antibody (mAb) structural integrity.
4. Advanced Downstream Purification & Analytical Characterization
- Enclosed tangential flow filtration (TFF), ultrafiltration/diafiltration (UF/DF), and preparative chromatography for aggregate and free-drug clearance.
- Comprehensive analytical release testing:
- DAR determination via Hydrophobic Interaction Chromatography (HIC) and Reverse-Phase HPLC.
- Aggregate and fragment analysis via Size-Exclusion Chromatography (SEC-HPLC).
- Intact mass and drug-loading distribution via LC-MS/MS.
- Free drug/payload limit testing down to trace ppm levels.